<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><?release-delay 0|0 ?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Biol Chem</journal-id><journal-id journal-id-type="hwp">jbc</journal-id><journal-id journal-id-type="pmc">jbc</journal-id><journal-id journal-id-type="publisher-id">JBC</journal-id><journal-title-group><journal-title>The Journal of Biological Chemistry</journal-title></journal-title-group><issn pub-type="ppub">0021-9258</issn><issn pub-type="epub">1083-351X</issn><publisher><publisher-name>American Society for Biochemistry and Molecular Biology</publisher-name><publisher-loc>9650 Rockville Pike, Bethesda, MD 20814, U.S.A.</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">3077580</article-id><article-id pub-id-type="publisher-id">C111.229096</article-id><article-id pub-id-type="doi">10.1074/jbc.C111.229096</article-id><article-categories><subj-group subj-group-type="heading"><subject>Reports</subject></subj-group></article-categories><title-group><article-title>The Anti-angiogenic Peptide Anginex Greatly Enhances Galectin-1 Binding Affinity for Glycoproteins<xref ref-type="fn" rid="FN1">*</xref><xref ref-type="fn" rid="FN2"><sup><inline-graphic xlink:href="sbox.jpg"/></sup></xref></article-title><alt-title alt-title-type="short">Report: Anginex Interaction with Galectin-1</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Salomonsson</surname><given-names>Emma</given-names></name><xref ref-type="aff" rid="aff1"><sup>&#8225;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Thijssen</surname><given-names>Victor L.</given-names></name><xref ref-type="aff" rid="aff2"><sup>&#167;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Griffioen</surname><given-names>Arjan W.</given-names></name><xref ref-type="aff" rid="aff2"><sup>&#167;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nilsson</surname><given-names>Ulf J.</given-names></name><xref ref-type="aff" rid="aff3"><sup>&#182;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Leffler</surname><given-names>Hakon</given-names></name><xref ref-type="aff" rid="aff1"><sup>&#8225;</sup></xref><xref ref-type="corresp" rid="cor1"><sup>1</sup></xref></contrib><aff id="aff1">From the <label>&#8225;</label>Section Microbiology, Immunology, Glycobiology, Institute of Laboratory Medicine, Lund University, S&#246;lvegatan 23, SE-223 62 Lund, Sweden, </aff><aff id="aff2">the <label>&#167;</label>Angiogenesis Laboratory, Cancer Center Amsterdam, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands, and </aff><aff id="aff3">the <label>&#182;</label>Organic Chemistry Division, Lund University, P. O. Box 124, SE-221 00 Lund, Sweden</aff></contrib-group><author-notes><corresp id="cor1"><label>1</label> To whom correspondence should be addressed. Tel.: <phone>46-46-173270</phone>; E-mail: <email>Hakon.Leffler@med.lu.se</email>.</corresp></author-notes><pub-date pub-type="ppub"><day>22</day><month>4</month><year>2011</year></pub-date><pub-date pub-type="epub"><day>3</day><month>3</month><year>2011</year></pub-date><pub-date pub-type="pmc-release"><day>3</day><month>3</month><year>2011</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. --><volume>286</volume><issue>16</issue><fpage>13801</fpage><lpage>13804</lpage><history><date date-type="received"><day>8</day><month>2</month><year>2011</year></date><date date-type="rev-recd"><day>2</day><month>3</month><year>2011</year></date></history><permissions><copyright-statement>&#169; 2011 by The American Society for Biochemistry and Molecular Biology, Inc.</copyright-statement><license license-type="open-access"><license-p><italic>Author's Choice</italic>&#8212;Final version full access.</license-p><license-p><ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">Creative Commons Attribution Non-Commercial License</ext-link> applies to Author Choice Articles</license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="zbc01611013801.pdf"/><abstract><p>Angiogenesis is a key event in cancer progression and therefore a promising target in cancer treatment. Galectin-1, a &#946;-galactoside binding lectin, is up-regulated in the endothelium of tumors of different origin and has been shown to be the target for anginex, a powerful anti-angiogenic peptide with anti-tumor activity. Here we show that when bound to anginex, galectin-1 binds various glycoproteins with hundred- to thousand-fold higher affinity. Anginex also interacts with galectin-2, -7, -8N, and -9N but not with galectin-3, -4, or -9C.</p></abstract><kwd-group><kwd>Cancer Therapy</kwd><kwd>Carbohydrate</kwd><kwd>Fluorescence</kwd><kwd>Glycoprotein</kwd><kwd>Lectin</kwd><kwd>Peptide Interactions</kwd><kwd>Angiogenesis</kwd><kwd>Fluorescence Polarization</kwd><kwd>Galactose</kwd><kwd>Galectin</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Anginex is a 33-mer cytokine-like artificial &#946;-peptide (the sequence is given in <ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/C111.229096/DC1">supplemental Fig. S1</ext-link>) that inhibits endothelial cell growth by specifically blocking adhesion and migration of activated endothelial cells leading to angiogenesis <italic>in vitro</italic> and <italic>in vivo</italic> (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). It inhibits microvessel formation but not the larger, pre-existing vessels, pointing toward tumor specificity (<xref ref-type="bibr" rid="B1">1</xref>). The profound anti-tumor effect is found both on tumor growth and on established tumors in human xenograft mouse models (<xref ref-type="bibr" rid="B2">2</xref>).</p><p>A two-hybrid screen using anginex as bait revealed the small soluble lectin galectin-1 as a potential target, and the requirement of galectin-1 for the anti-angiogenic effect of anginex was demonstrated using galectin-1-null mutant mice (<xref ref-type="bibr" rid="B3">3</xref>). This and other studies on galectin-1 (<xref ref-type="bibr" rid="B4">4</xref>&#8211;<xref ref-type="bibr" rid="B6">6</xref>) suggested a rate-limiting role of galectin-1 in tumor angiogenesis and indicated that anginex interferes with the pro-angiogenic effect of galectin-1.</p><p>Galectin-1 consists of an &#8764;135-amino acid canonical galectin carbohydrate recognition domain (CRD),<xref ref-type="fn" rid="FN3"><sup>2</sup></xref> which exists as a mixture of monomers and dimers at physiological concentrations (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>). Similar to other galectins, its main known biochemical function is to bind &#946;-galactoside-containing glycoproteins and cross-link them, which may result in various cellular signals and consequent effects in immunity, inflammation, and cancer (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B9">9</xref>). Therefore we analyzed the effect of anginex on the carbohydrate binding activity of galectin-1, with the hypothesis that it would act as an inhibitor. Surprisingly, we instead found that anginex may strongly enhance binding of galectin-1 to certain glycoconjugates.</p></sec><sec sec-type="methods"><title>EXPERIMENTAL PROCEDURES</title><sec><title/><sec><title/><sec><title>Galectins, Glycoproteins, and Chemicals</title><p>Plasmids encoding human galectin-1 (gift from Professor Richard Cummings, Department of Biochemistry, Emory School of Medicine, Atlanta, GA) and human galectin-1 C3S (gift from Dr. Jun Hirabayashi, Research Center for Glycoscience, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Japan) were expressed in <italic>Escherichia coli</italic>, and galectins were purified by affinity chromatography on lactosyl-Sepharose and characterized as described before (<xref ref-type="bibr" rid="B8">8</xref>). The other galectins were produced and purified in an analogous way as described (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>). The oxidation-resistant mutant, galectin-1 C3S (galectin-1), was used in most experiments to avoid having to include &#946;-mercaptoethanol, which may perturb interacting glycoprotein ligands, and was shown to have the same specificity and affinity as wild type galectin-1 for a wide range of saccharides, probes, and glycoproteins (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B12">12</xref>). Anginex and an inactive control peptide (<ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/C111.229096/DC1">supplemental Fig. S1</ext-link>) (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B13">13</xref>) and fluorescein-tagged saccharide probes (<ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/C111.229096/DC1">supplemental Fig. S2</ext-link>) (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B14">14</xref>) were as described before. Asialofetuin (ASF), fetuin, haptoglobin, and bovine serum albumin (BSA) were from Sigma. All dilutions were prepared in 10% PBS buffer (12 m<sc>m</sc> NaCl, 7 m<sc>m</sc> Na/K-phosphate, pH 7.2) because anginex stock solutions precipitate in high salt buffers; there was no evidence for any difference in affinity and specificity of galectin-1 for small saccharides and probes between PBS and 10% PBS buffer. High concentration of galectin-1 did not cause aggregation of ASF in 10% PBS buffer as it does in PBS, but the affinities were only marginally lower in 10% PBS buffer (<italic>K<sub>d</sub></italic> &#8764;5 &#956;<sc>m</sc> as compared with &#8764;3 &#956;<sc>m</sc> for ASF and 50 &#956;<sc>m</sc> as compared with 40 &#956;<sc>m</sc> for fetuin).</p></sec><sec><title>Fluorescence Anisotropy</title><p>Affinities of probes and inhibitors for galectin-1 were measured with fluorescence anisotropy (FA) and calculated as described (<xref ref-type="bibr" rid="B8">8</xref>). Details are given in the figure legends. All graphs were generated using Prism 4 (GraphPad Software Inc.).</p></sec></sec></sec></sec><sec sec-type="results|discussion"><title>RESULTS AND DISCUSSION</title><p>The interaction between anginex and galectin-1 was investigated using an FA assay (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B15">15</xref>). In this assay, the interactions of galectin-1 with fluorescein-tagged saccharide probes were studied, as well as the perturbing effects of potential inhibitors/modifiers. With a fixed concentration of a newly designed high affinity <bold>tdga-probe</bold> (<xref ref-type="bibr" rid="B8">8</xref>) (<ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/C111.229096/DC1">supplemental Fig. S2<italic>A</italic></ext-link>) and increasing concentrations of galectin-1, the anisotropy rose from a value of &#8764;30 mA (<italic>A</italic><sub>0</sub> = anisotropy of the free probe) to &#8764;170 mA (<italic>A</italic><sub>max</sub> = anisotropy of the galectin-probe complex) following a curve of shape consistent with a 1:1 interaction and position along <italic>x</italic> axis consistent with a <italic>K<sub>d</sub></italic> &#8764;0.4 &#956;<sc>m</sc>. With the same probe and galectin concentrations in the presence of 8 &#956;<sc>m</sc> anginex (<xref ref-type="fig" rid="F1">Fig. 1</xref><italic>A</italic>), the curve shifted to the left, indicative of higher binding affinity (<italic>K<sub>d</sub></italic> &#8764;0.02 &#956;<sc>m</sc>), and <italic>A</italic><sub>max</sub> became higher (&#8764;235 mA), indicative of more restricted mobility of the fluorescein tag in the galectin-probe complex. With the <bold>LNT-probe</bold> (<ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/C111.229096/DC1">supplemental Fig. S2<italic>B</italic></ext-link>), there was no rise in the anisotropy with increasing galectin-1 concentrations, due in part to lower affinity (<italic>K<sub>d</sub></italic> &#8764;100 &#956;<sc>m</sc>) but also higher segmental mobility of the fluorescein tag even in the galectin-probe complex, probably because the galectin binds the terminal disaccharide (as indicated in <ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/C111.229096/DC1">supplemental Fig. S2<italic>B</italic></ext-link> and discussed in detail for other galectins (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B14">14</xref>)). In the presence of anginex, however, the <bold>LNT-probe</bold> also gave a clear rise in anisotropy (to &#8764;120 mA) and a curve consistent with a <italic>K<sub>d</sub></italic> &#8764;5 &#956;<sc>m</sc> (<xref ref-type="fig" rid="F1">Fig. 1</xref><italic>B</italic>). With both probes, in the presence of anginex, the anisotropy values started to drop when the galectin concentration started to exceed the anginex concentration, most likely due to competition by anginex-free galectin for the probe.</p><fig id="F1" position="float"><label>FIGURE 1.</label><caption><p><bold>Effect of anginex on the interaction of galectin-1 with fluorescein-labeled saccharide probes.</bold> <italic>A</italic> and <italic>B</italic>, a range of different concentrations of galectin-1 was added to a microtiter plate together with a fixed concentration (0.1 &#956;<sc>m</sc>) of <bold>tdga-probe</bold> (<italic>A</italic>) or <bold>LNT-probe</bold> (<italic>B</italic>) in 8 &#956;<sc>m</sc> anginex or 10% PBS buffer, and fluorescence anisotropy was measured using a PolarStar plate reader. Binding curves were generated by plotting anisotropy against increasing concentrations of galectin-1. <italic>C</italic> and <italic>D</italic>, fixed low concentrations of galectin-1 (12 or 48 n<sc>m</sc>) were mixed with a range of concentrations of <bold>tdga-probe</bold> in the presence of 8 &#956;<sc>m</sc> (<italic>C</italic>) or 4 &#956;<sc>m</sc> (<italic>D</italic>) anginex. Fractions of bound probe were calculated ((<italic>A</italic> &#8722; <italic>A</italic><sub>0</sub>)/(<italic>A</italic><sub>max</sub> &#8722; <italic>A</italic><sub>0</sub>)), and from this, fractions of free probe (total &#8722; bound) were calculated. Finally, bound <bold>tdga-probe</bold> was plotted against bound/free <bold>tdga-probe</bold> to construct Scatchard plots. In <italic>D</italic>, linear regression was made with a fixed <italic>K<sub>d</sub></italic> = 25 n<sc>m</sc>, as found for 8 &#956;<sc>m</sc> anginex. Graphs were made using Prism 4 (GraphPad Software Inc.). The structures of the probes are shown in <ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/C111.229096/DC1">supplemental Fig. S2</ext-link>.</p></caption><graphic xlink:href="zbc0201160220001"/></fig><p>For a more detailed assessment of the affinity of the <bold>tdga-probe</bold> for the galectin-1-anginex complex, fixed low concentrations of galectin-1 (12 and 48 n<sc>m</sc>, not causing significant probe binding by themselves) were mixed with 8 &#956;<sc>m</sc> anginex and analyzed with a range of different concentrations of the probe. From the anisotropy data, the concentrations of free and bound probe were calculated and used to construct Scatchard plots. These showed that the <bold>tdga-probe</bold> interacted with the galectin-1-anginex complex with <italic>K<sub>d</sub></italic> &#8764;25 n<sc>m</sc> (<xref ref-type="fig" rid="F1">Fig. 1</xref><italic>C</italic>), which is &#8764;16-fold higher affinity than for free galectin-1. The estimated concentration of these high affinity sites (from the <italic>x</italic>-intercept) was &#8764;39 n<sc>m</sc> with 48 n<sc>m</sc> galectin-1 and 9.3 n<sc>m</sc> with 12 n<sc>m</sc> galectin-1; that is, about 80% of the available galectin would be in complex with anginex. With 4 &#956;<sc>m</sc> anginex, the Scatchard plot was consistent with &#8764;25 n<sc>m</sc> high affinity sites in 48 n<sc>m</sc> galectin-1 (&#8764;50% of the added galectin), and in addition, lower affinity sites were detected at the highest probe concentrations, probably due to free galectin-1. These data are consistent with the affinity of anginex for immobilized galectin-1 in surface plasmon resonance (<xref ref-type="bibr" rid="B3">3</xref>).</p><p>To analyze the effect of anginex on non-labeled ligands, we added these as inhibitors of the galectin-1-probe interaction as described previously (<xref ref-type="bibr" rid="B8">8</xref>). In the first type of assay, a range of concentrations of the glycoproteins ASF and fetuin was added to fixed low concentrations of galectin-1 (0.25 &#956;<sc>m</sc>) and <bold>tdga-probe</bold> (0.1 &#956;<sc>m</sc>) in the presence or absence of 8 &#956;<sc>m</sc> anginex, anisotropy was measured, and the percentages of bound probe and <italic>K<sub>d</sub></italic> values were calculated. In the absence of anginex, this produced <italic>K<sub>d</sub></italic> values (assuming one binding site) of &#8764;5 &#956;<sc>m</sc> for ASF and &#8764;50 &#956;<sc>m</sc> for fetuin (<xref ref-type="fig" rid="F2">Fig. 2</xref>, <italic>A</italic> and <italic>B</italic>), in agreement with the previous results (Table 2 and supplemental Table S3 in Ref. <xref ref-type="bibr" rid="B8">8</xref>). In the presence of 8 &#956;<sc>m</sc> anginex, there was a dramatic shift of the inhibition curves to the left, indicative of much lower <italic>K<sub>d</sub></italic> values, &#8764;10 n<sc>m</sc> for ASF and 20 n<sc>m</sc> for fetuin, an increase in inhibitory potency of 500 and 2500 times, respectively.</p><fig id="F2" position="float"><label>FIGURE 2.</label><caption><p><bold>Effect of anginex on galectin-1 interaction with glycoproteins ASF, fetuin, and haptoglobin.</bold> <italic>A</italic> and <italic>B</italic>, increasing concentrations of ASF (<italic>A</italic>) or fetuin (<italic>B</italic>) were mixed with 0.1 &#956;<sc>m</sc> <bold>tdga-probe</bold> and 0.25 &#956;<sc>m</sc> galectin-1 in the presence or absence of 8 &#956;<sc>m</sc> anginex, and anisotropy was measured. The percentage of bound probe was calculated as 100 &#215; (<italic>A</italic> &#8722; <italic>A</italic><sub>0</sub>)/(<italic>A</italic><sub>no inhibitor</sub> &#8722; <italic>A</italic><sub>0</sub>) and plotted against inhibitor concentration. The inhibition curve goes down to 0% bound probe for ASF because after the anginex-galectin-1 complex has been saturated, the ASF concentration (low &#956;<sc>m</sc>) is also enough to inhibit remaining free galectin-1 (<italic>A</italic>). However, this is not the case for fetuin, where a residual of about 10&#8211;20% bound probe is observed even at higher fetuin concentrations, which may be due to the fact that fetuin is a poor inhibitor for free galectin-1. <italic>C</italic> and <italic>D</italic>, increasing concentrations of galectin-1 were added to a fixed concentration of <bold>tdga-probe</bold> (0.1 &#956;<sc>m</sc>) and 0.1 &#956;<sc>m</sc> ASF or fetuin in the presence of 8 &#956;<sc>m</sc> anginex (<italic>C</italic>) or without anginex (<italic>D</italic>). The percentage of bound <bold>tdga-probe</bold> was calculated and plotted against increasing concentration of galectin-1. BSA (<italic>C</italic>, <italic>inset</italic>) was run as a non-binding control. <italic>E</italic>, the percentage of bound probe was used to estimate the concentration of free galectin-1 in the presence of glycoprotein using the values in its absence as a standard curve, and then the concentration of glycoprotein-bound galectin-1 was calculated (total &#8722; free &#8722; probe-bound), and Scatchard plots were constructed as described previously (Fig. 6 in Ref. <xref ref-type="bibr" rid="B8">8</xref>). Data points in <italic>parenthesis</italic> were not included in the linear regression calculation. <italic>F</italic>, same as in <italic>C</italic>, but with 0.1 &#956;<sc>m</sc> haptoglobin as inhibitor and without anginex (as in <italic>D</italic>) as <italic>inset</italic>.</p></caption><graphic xlink:href="zbc0201160220002"/></fig><p>To determine how many of the nine potential galectin-1 binding sites on ASF (<xref ref-type="bibr" rid="B16">16</xref>) become occupied, we used a second type of assay, which previously identified one high affinity galectin-1 binding site (<italic>K<sub>d</sub></italic> &#8764;3 &#956;<sc>m</sc>) using the <bold>tdga-probe</bold> and another eight lower affinity sites using another low affinity probe (<xref ref-type="bibr" rid="B8">8</xref>). In this assay type, a range of galectin concentrations was mixed with fixed concentrations of <bold>tdga-probe</bold> (0.1 &#956;<sc>m</sc>), glycoprotein (0 or 0.1 &#956;<sc>m</sc>), and anginex (0 or 8 &#956;<sc>m</sc>), the percentage of bound probe was calculated from the fluorescence anisotropy (<xref ref-type="fig" rid="F2">Fig. 2</xref><italic>C</italic>), and the concentrations of free and glycoprotein-bound galectin-1 were calculated to construct Scatchard plots (<xref ref-type="fig" rid="F2">Fig. 2</xref><italic>E</italic>). Inhibition by the glycoprotein is seen as a shift of the binding curve to the right (<xref ref-type="fig" rid="F2">Fig. 2</xref><italic>C</italic>). Without anginex, there was no inhibition (<xref ref-type="fig" rid="F2">Fig. 2</xref><italic>D</italic>) because the glycoprotein concentration used here (0.1 &#956;<sc>m</sc>) was much lower as compared with that used previously (20&#8211;40 &#956;<sc>m</sc>) (<xref ref-type="bibr" rid="B8">8</xref>). However, in 8 &#956;<sc>m</sc> anginex, there was a clear shift of the curves for both glycoproteins (<xref ref-type="fig" rid="F2">Fig. 2</xref><italic>C</italic>). BSA, which does not bind galectin-1, did not give a curve shift even in the presence of anginex (<xref ref-type="fig" rid="F2">Fig. 2</xref><italic>C</italic>, <italic>inset</italic>), which validates the assay. The Scatchard plots indicated about 1.5 binding sites per molecule for ASF and about 1 for fetuin, similar to that found with the <bold>tdga-probe</bold> in the absence of anginex (<xref ref-type="bibr" rid="B8">8</xref>), but with several hundred- to thousand-fold higher affinities (<italic>K<sub>d</sub></italic> &#8764;15 n<sc>m</sc>). We also analyzed the interaction of galectin-1 with haptoglobin, a naturally occurring human serum glycoprotein (<xref ref-type="fig" rid="F2">Fig. 2</xref><italic>F</italic>). A clear shift of the binding curve was found in the presence of anginex but not in its absence (<italic>inset</italic>), suggesting enhanced affinity of galectin-1 also for this glycoprotein in the presence of anginex. In contrast, the inhibitory potencies of small saccharides, Gal&#946;1-4Glc&#946;-<italic>O</italic>-Me and Gal&#946;1-4GlcNAc&#946;-<italic>O</italic>-Me, known to bind galectin-1 (<xref ref-type="bibr" rid="B8">8</xref>), were not enhanced in the presence of anginex (not shown).</p><p>Anginex was selected based on its anti-angiogenic activity from a panel of &#8764;30 different designed peptides with small variations in sequence (<xref ref-type="bibr" rid="B1">1</xref>). From this panel of peptides, &#946;pep-28 (<ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/C111.229096/DC1">supplemental Fig. S1</ext-link>) has been shown to have a similar structure as anginex (<xref ref-type="bibr" rid="B13">13</xref>) but to be biologically inactive, and hence, it has been used as a negative control (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). In the FA assay, this peptide also had no effect either when it was analyzed with galectin-1 and the two probes, at concentrations where the addition of anginex would result in the maximal increase in fluorescence anisotropy (<xref ref-type="fig" rid="F3">Fig. 3</xref><italic>A</italic>), or when screened with a range of galectin-1 concentrations (<xref ref-type="fig" rid="F3">Fig. 3</xref><italic>B</italic>), as done with anginex in <xref ref-type="fig" rid="F1">Fig. 1</xref><italic>A</italic>. This shows that the interaction of anginex with galectin-1 in the FA assay is specific and correlates with its biological activity. The concentrations (low &#956;<sc>m</sc>) of anginex required for the effects in the FA assay described above are also in the same range as those required for its biological effects (<xref ref-type="bibr" rid="B1">1</xref>).</p><fig id="F3" position="float"><label>FIGURE 3.</label><caption><p><bold>Effect of a control peptide, &#946;pep-28, and the effect of anginex on other galectins.</bold> <italic>A</italic>, 0.1 &#956;<sc>m</sc> <bold>tdga-probe</bold> or <bold>LNT-probe</bold> was mixed with 0.1 or 3 &#956;<sc>m</sc> galectin-1, respectively, in the presence of 8 &#956;<sc>m</sc> anginex, 8 &#956;<sc>m</sc> &#946;pep-28, or no peptide, and anisotropy was measured. Free probes (<italic>A</italic><sub>0</sub>) were run in parallel. Increased anisotropy (<italic>A</italic><sub>peptide</sub> &#8722; <italic>A</italic><sub>no peptide</sub>) (<italic>y</italic> axis) was calculated with <italic>A</italic><sub>peptide</sub> = <italic>A</italic> &#8722; <italic>A</italic><sub>0</sub> in anginex or &#946;pep-28 and <italic>A</italic><sub>no</sub> <sub>peptide</sub> = <italic>A</italic> &#8722; <italic>A</italic><sub>0</sub> in the absence of peptide. The amino acid sequences of anginex and &#946;pep-28 are shown in <ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/C111.229096/DC1">supplemental Fig. S1</ext-link>. <italic>B</italic>, a range of different concentrations of galectin-1 was analyzed with a fixed concentration (0.1 &#956;<sc>m</sc>) of <bold>tdga-probe</bold> in the same way as in <xref ref-type="fig" rid="F1">Fig. 1</xref><italic>A</italic> but in the presence or absence of 8 &#956;<sc>m</sc> &#946;pep-28 instead of anginex. <italic>C</italic>, different combinations of probe (0.1 &#956;<sc>m</sc>) and galectin (<bold>tdga-probe</bold>: 0.5 &#956;<sc>m</sc> galectin-1, 10 &#956;<sc>m</sc> galectin-2, 3 &#956;<sc>m</sc> galectin-4N, 2 &#956;<sc>m</sc> galectin-9C; <bold>A-tetra-saccharide-probe</bold> (<xref ref-type="bibr" rid="B14">14</xref>): 1 &#956;<sc>m</sc> galectin-3, 0.5 &#956;<sc>m</sc> galectin-4, 0.5 &#956;<sc>m</sc> galectin-4C; <bold>LNnT-probe</bold> (<xref ref-type="bibr" rid="B14">14</xref>): 2 &#956;<sc>m</sc> galectin-7; <bold>LNnT-probe</bold> (<xref ref-type="bibr" rid="B23">23</xref>): 0.4 &#956;<sc>m</sc> galectin-8N, 0.4 &#956;<sc>m</sc> galectin-8S, and 1 &#956;<sc>m</sc> galectin-9N) were analyzed in the presence or absence of 16 &#956;<sc>m</sc> anginex. The different probe-galectin combinations and concentrations were chosen to ensure binding in the absence of anginex. 16 &#956;<sc>m</sc> anginex was used instead of 8 &#956;<sc>m</sc> to exceed the highest galectin concentration (10 &#956;<sc>m</sc> for galectin-2). Free probes were measured in parallel, and increased anisotropy (<italic>A</italic><sub>anginex</sub> &#8722; <italic>A</italic><sub>no anginex</sub>) (<italic>y</italic> axis) was calculated with <italic>A</italic><sub>anginex</sub> = A &#8722; <italic>A</italic><sub>0</sub> in anginex and <italic>A</italic><sub>no anginex</sub> = <italic>A</italic> &#8722; <italic>A</italic><sub>0</sub> without anginex. <italic>Error bars</italic> in <italic>A</italic> and <italic>C</italic> indicate S.E.</p></caption><graphic xlink:href="zbc0201160220003"/></fig><p>We finally assessed the effect of anginex on other members of the galectin family. Anginex was added to different galectins, at fixed concentrations with different probes selected based on our extensive use of the FA assay, to test galectin inhibitors (<xref ref-type="bibr" rid="B11">11</xref>). Galectin-2 and -7 and the N-terminal CRDs of galectin-8 and -9, but not galectin-3 and -4 and the C-terminal CRD of galectin-9, showed an increased anisotropy, indicating interaction with anginex (<xref ref-type="fig" rid="F3">Fig. 3</xref><italic>C</italic>).</p><p>In summary, we have found that the synthetic anti-angiogenic peptide anginex dramatically enhances the affinity of galectin-1 for certain ligands, including biologically relevant glycoproteins. In fact, this apparently monovalent interaction has among the highest affinities (<italic>K<sub>d</sub></italic> low n<sc>m</sc>) ever reported for a lectin. To elucidate the precise mechanism of this and its consequences in cellular systems will require further study.</p><p>Because anginex tends to form dimers and larger aggregates (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B13">13</xref>), the mechanism for its effect may entail increased cross-linking of galectin-1. However, more specific conformational modification of a single CRD is also possible.</p><p>One possible general explanation for the biological effects of anginex may be due to shifts of galectin-1 receptor binding equilibria. Many of the proposed regulatory effects of galectin-1 appear to involve reversible binding to receptors with affinities in the low &#956;<sc>m</sc> range (<xref ref-type="bibr" rid="B17">17</xref>&#8211;<xref ref-type="bibr" rid="B19">19</xref>), perhaps with reversible formation and dissolution of cross-linked lattices (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B21">21</xref>). If affinity for certain ligands were increased hundred- to thousand-fold, as seen here, such equilibria would be dramatically altered.</p><p>The anginex effect on galectin-1 may also mimic a normal function; it is hard to believe that an artificial peptide can show such dramatic effects without speculating that there is a natural counterpart <italic>in vivo</italic>. This also becomes an intriguing thought because galectin-1 in some cases showed biological effects at n<sc>m</sc> concentrations (<italic>e.g.</italic> <xref ref-type="fig" rid="F3">Fig. 3</xref> in Ref. <xref ref-type="bibr" rid="B6">6</xref>) or surprisingly little was needed to rescue the null phenotype in mice <italic>in vivo</italic> (<xref ref-type="bibr" rid="B22">22</xref>) despite the fact that, as mentioned above, most known ligands have affinities in the &#956;<sc>m</sc> range. There are many text book cases where strong binding activity of one protein is induced by another protein or smaller molecule, but it has not been found before for the carbohydrate binding activity of galectins, or perhaps not even lectins in general (except for cations). The fluorescence anisotropy assay used here provides a simple screening method to find natural modifiers of galectin ligand binding and also to select designed peptides with similar effects, for example, in the search for new improved versions of anginex as anti-cancer agents.</p></sec></body><back><fn-group><fn fn-type="supported-by" id="FN1"><label>*</label><p>This work was supported by grants from the Lund University Research School in Pharmaceutical Sciences, the Swedish Research Council Grants 2009-5656 (to H. L.) and 2009-5326 (to U. J. N.), and Dutch Cancer Society Grants UM2008-4101 and VU2009-4358 (to V. L. T. and A. W. G.).</p></fn><fn fn-type="supplementary-material" id="FN2"><label><inline-graphic xlink:href="sbox.jpg"/></label><p>The on-line version of this article (available at <ext-link ext-link-type="uri" xlink:href="http://www.jbc.org">http://www.jbc.org</ext-link>) contains <ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/C111.229096/DC1">supplemental Figs. S1 and S2</ext-link>.</p></fn></fn-group><fn-group content-type="abbreviations"><fn id="FN3"><label>2</label><p>The abbreviations used are:
<def-list><def-item><term id="G1">CRD</term><def><p>carbohydrate recognition domain</p></def></def-item><def-item><term id="G2">FA</term><def><p>fluorescence anisotropy</p></def></def-item><def-item><term id="G3">tdga</term><def><p>thiodigalactoside amide</p></def></def-item><def-item><term id="G4">LNT</term><def><p>lacto-<italic>N</italic>-tetraose (Gal&#946;1-3GlcNAc&#946;1-3Gal&#946;1-4Glc)</p></def></def-item><def-item><term id="G5">ASF</term><def><p>asialofetuin</p></def></def-item><def-item><term id="G6">LNnT</term><def><p>lacto-<italic>N</italic>-neotetraose (Gal&#946;1-4GlcNAc&#946;1-3Gal&#946;1-4Glc).</p></def></def-item></def-list></p></fn></fn-group><ack><title>Acknowledgments</title><p>We thank Professor Kevin Mayo, Department of Biochemistry, University of Minnesota, Minneapolis, MN for providing the peptides anginex and &#946;pep-28 and Barbro Kahl-Knutson for excellent technical help and valuable comments.</p></ack><ref-list><title>REFERENCES</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Griffioen</surname><given-names>A. W.</given-names></name><name><surname>van der Schaft</surname><given-names>D. W.</given-names></name><name><surname>Barendsz-Janson</surname><given-names>A. F.</given-names></name><name><surname>Cox</surname><given-names>A.</given-names></name><name><surname>Struijker Boudier</surname><given-names>H. A.</given-names></name><name><surname>Hillen</surname><given-names>H. F.</given-names></name><name><surname>Mayo</surname><given-names>K. H.</given-names></name></person-group> (<year>2001</year>) <source>Biochem. J.</source> <volume>354</volume>, <fpage>233</fpage>&#8211;<lpage>242</lpage><pub-id pub-id-type="pmid">11171099</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van der Schaft</surname><given-names>D. W.</given-names></name><name><surname>Dings</surname><given-names>R. P.</given-names></name><name><surname>de Lussanet</surname><given-names>Q. G.</given-names></name><name><surname>van Eijk</surname><given-names>L. I.</given-names></name><name><surname>Nap</surname><given-names>A. W.</given-names></name><name><surname>Beets-Tan</surname><given-names>R. G.</given-names></name><name><surname>Bouma-Ter Steege</surname><given-names>J. C.</given-names></name><name><surname>Wagstaff</surname><given-names>J.</given-names></name><name><surname>Mayo</surname><given-names>K. H.</given-names></name><name><surname>Griffioen</surname><given-names>A. W.</given-names></name></person-group> (<year>2002</year>) <source>FASEB J.</source> <volume>16</volume>, <fpage>1991</fpage>&#8211;<lpage>1993</lpage><pub-id pub-id-type="pmid">12397082</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thijssen</surname><given-names>V. L.</given-names></name><name><surname>Postel</surname><given-names>R.</given-names></name><name><surname>Brandwijk</surname><given-names>R. J.</given-names></name><name><surname>Dings</surname><given-names>R. P.</given-names></name><name><surname>Nesmelova</surname><given-names>I.</given-names></name><name><surname>Satijn</surname><given-names>S.</given-names></name><name><surname>Verhofstad</surname><given-names>N.</given-names></name><name><surname>Nakabeppu</surname><given-names>Y.</given-names></name><name><surname>Baum</surname><given-names>L. G.</given-names></name><name><surname>Bakkers</surname><given-names>J.</given-names></name><name><surname>Mayo</surname><given-names>K. H.</given-names></name><name><surname>Poirier</surname><given-names>F.</given-names></name><name><surname>Griffioen</surname><given-names>A. W.</given-names></name></person-group> (<year>2006</year>) <source>Proc. Natl. Acad. Sci. U.S.A.</source> <volume>103</volume>, <fpage>15975</fpage>&#8211;<lpage>15980</lpage><pub-id pub-id-type="pmid">17043243</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thijssen</surname><given-names>V. L.</given-names></name><name><surname>Poirier</surname><given-names>F.</given-names></name><name><surname>Baum</surname><given-names>L. G.</given-names></name><name><surname>Griffioen</surname><given-names>A. W.</given-names></name></person-group> (<year>2007</year>) <source>Blood</source> <volume>110</volume>, <fpage>2819</fpage>&#8211;<lpage>2827</lpage><pub-id pub-id-type="pmid">17591944</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Le Mercier</surname><given-names>M.</given-names></name><name><surname>Fortin</surname><given-names>S.</given-names></name><name><surname>Mathieu</surname><given-names>V.</given-names></name><name><surname>Kiss</surname><given-names>R.</given-names></name><name><surname>Lefranc</surname><given-names>F.</given-names></name></person-group> (<year>2010</year>) <source>Brain Pathol.</source> <volume>20</volume>, <fpage>17</fpage>&#8211;<lpage>27</lpage><pub-id pub-id-type="pmid">19371355</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thijssen</surname><given-names>V. L.</given-names></name><name><surname>Barkan</surname><given-names>B.</given-names></name><name><surname>Shoji</surname><given-names>H.</given-names></name><name><surname>Aries</surname><given-names>I. M.</given-names></name><name><surname>Mathieu</surname><given-names>V.</given-names></name><name><surname>Deltour</surname><given-names>L.</given-names></name><name><surname>Hackeng</surname><given-names>T. M.</given-names></name><name><surname>Kiss</surname><given-names>R.</given-names></name><name><surname>Kloog</surname><given-names>Y.</given-names></name><name><surname>Poirier</surname><given-names>F.</given-names></name><name><surname>Griffioen</surname><given-names>A. W.</given-names></name></person-group> (<year>2010</year>) <source>Cancer Res.</source> <volume>70</volume>, <fpage>6216</fpage>&#8211;<lpage>6224</lpage><pub-id pub-id-type="pmid">20647324</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leffler</surname><given-names>H.</given-names></name><name><surname>Carlsson</surname><given-names>S.</given-names></name><name><surname>Hedlund</surname><given-names>M.</given-names></name><name><surname>Qian</surname><given-names>Y.</given-names></name><name><surname>Poirier</surname><given-names>F.</given-names></name></person-group> (<year>2004</year>) <source>Glycoconj. J.</source> <volume>19</volume>, <fpage>433</fpage>&#8211;<lpage>440</lpage><pub-id pub-id-type="pmid">14758066</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Salomonsson</surname><given-names>E.</given-names></name><name><surname>Larumbe</surname><given-names>A.</given-names></name><name><surname>Tejler</surname><given-names>J.</given-names></name><name><surname>Tullberg</surname><given-names>E.</given-names></name><name><surname>Rydberg</surname><given-names>H.</given-names></name><name><surname>Sundin</surname><given-names>A.</given-names></name><name><surname>Khabut</surname><given-names>A.</given-names></name><name><surname>Frejd</surname><given-names>T.</given-names></name><name><surname>Lobsanov</surname><given-names>Y. D.</given-names></name><name><surname>Rini</surname><given-names>J. M.</given-names></name><name><surname>Nilsson</surname><given-names>U. J.</given-names></name><name><surname>Leffler</surname><given-names>H.</given-names></name></person-group> (<year>2010</year>) <source>Biochemistry</source> <volume>49</volume>, <fpage>9518</fpage>&#8211;<lpage>9532</lpage></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rabinovich</surname><given-names>G. A.</given-names></name><name><surname>Toscano</surname><given-names>M. A.</given-names></name></person-group> (<year>2009</year>) <source>Nat. Rev. Immunol.</source> <volume>9</volume>, <fpage>338</fpage>&#8211;<lpage>352</lpage><pub-id pub-id-type="pmid">19365409</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Salomonsson</surname><given-names>E.</given-names></name><name><surname>Carlsson</surname><given-names>M. C.</given-names></name><name><surname>Osla</surname><given-names>V.</given-names></name><name><surname>Hendus-Altenburger</surname><given-names>R.</given-names></name><name><surname>Kahl-Knutson</surname><given-names>B.</given-names></name><name><surname>Oberg</surname><given-names>C. T.</given-names></name><name><surname>Sundin</surname><given-names>A.</given-names></name><name><surname>Nilsson</surname><given-names>R.</given-names></name><name><surname>Nordberg-Karlsson</surname><given-names>E.</given-names></name><name><surname>Nilsson</surname><given-names>U. J.</given-names></name><name><surname>Karlsson</surname><given-names>A.</given-names></name><name><surname>Rini</surname><given-names>J. M.</given-names></name><name><surname>Leffler</surname><given-names>H.</given-names></name></person-group> (<year>2010</year>) <source>J. Biol. Chem.</source> <volume>285</volume>, <fpage>35079</fpage>&#8211;<lpage>35091</lpage><pub-id pub-id-type="pmid">20807768</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cumpstey</surname><given-names>I.</given-names></name><name><surname>Salomonsson</surname><given-names>E.</given-names></name><name><surname>Sundin</surname><given-names>A.</given-names></name><name><surname>Leffler</surname><given-names>H.</given-names></name><name><surname>Nilsson</surname><given-names>U. J.</given-names></name></person-group> (<year>2008</year>) <source>Chemistry</source> <volume>14</volume>, <fpage>4233</fpage>&#8211;<lpage>4245</lpage><pub-id pub-id-type="pmid">18366047</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nishi</surname><given-names>N.</given-names></name><name><surname>Abe</surname><given-names>A.</given-names></name><name><surname>Iwaki</surname><given-names>J.</given-names></name><name><surname>Yoshida</surname><given-names>H.</given-names></name><name><surname>Itoh</surname><given-names>A.</given-names></name><name><surname>Shoji</surname><given-names>H.</given-names></name><name><surname>Kamitori</surname><given-names>S.</given-names></name><name><surname>Hirabayashi</surname><given-names>J.</given-names></name><name><surname>Nakamura</surname><given-names>T.</given-names></name></person-group> (<year>2008</year>) <source>Glycobiology</source> <volume>18</volume>, <fpage>1065</fpage>&#8211;<lpage>1073</lpage><pub-id pub-id-type="pmid">18796645</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arroyo</surname><given-names>M. M.</given-names></name><name><surname>Mayo</surname><given-names>K. H.</given-names></name></person-group> (<year>2007</year>) <source>Biochim. Biophys. Acta</source> <volume>1774</volume>, <fpage>645</fpage>&#8211;<lpage>651</lpage><pub-id pub-id-type="pmid">17478129</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carlsson</surname><given-names>S.</given-names></name><name><surname>Oberg</surname><given-names>C. T.</given-names></name><name><surname>Carlsson</surname><given-names>M. C.</given-names></name><name><surname>Sundin</surname><given-names>A.</given-names></name><name><surname>Nilsson</surname><given-names>U. J.</given-names></name><name><surname>Smith</surname><given-names>D.</given-names></name><name><surname>Cummings</surname><given-names>R. D.</given-names></name><name><surname>Almkvist</surname><given-names>J.</given-names></name><name><surname>Karlsson</surname><given-names>A.</given-names></name><name><surname>Leffler</surname><given-names>H.</given-names></name></person-group> (<year>2007</year>) <source>Glycobiology</source> <volume>17</volume>, <fpage>663</fpage>&#8211;<lpage>676</lpage><pub-id pub-id-type="pmid">17339281</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>S&#246;rme</surname><given-names>P.</given-names></name><name><surname>Kahl-Knutsson</surname><given-names>B.</given-names></name><name><surname>Huflejt</surname><given-names>M.</given-names></name><name><surname>Nilsson</surname><given-names>U. J.</given-names></name><name><surname>Leffler</surname><given-names>H.</given-names></name></person-group> (<year>2004</year>) <source>Anal. Biochem.</source> <volume>334</volume>, <fpage>36</fpage>&#8211;<lpage>47</lpage><pub-id pub-id-type="pmid">15464951</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dam</surname><given-names>T. K.</given-names></name><name><surname>Gabius</surname><given-names>H. J.</given-names></name><name><surname>Andr&#233;</surname><given-names>S.</given-names></name><name><surname>Kaltner</surname><given-names>H.</given-names></name><name><surname>Lensch</surname><given-names>M.</given-names></name><name><surname>Brewer</surname><given-names>C. F.</given-names></name></person-group> (<year>2005</year>) <source>Biochemistry</source> <volume>44</volume>, <fpage>12564</fpage>&#8211;<lpage>12571</lpage><pub-id pub-id-type="pmid">16156668</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cederfur</surname><given-names>C.</given-names></name><name><surname>Salomonsson</surname><given-names>E.</given-names></name><name><surname>Nilsson</surname><given-names>J.</given-names></name><name><surname>Halim</surname><given-names>A.</given-names></name><name><surname>Oberg</surname><given-names>C. T.</given-names></name><name><surname>Larson</surname><given-names>G.</given-names></name><name><surname>Nilsson</surname><given-names>U. J.</given-names></name><name><surname>Leffler</surname><given-names>H.</given-names></name></person-group> (<year>2008</year>) <source>Glycobiology</source> <volume>18</volume>, <fpage>384</fpage>&#8211;<lpage>394</lpage><pub-id pub-id-type="pmid">18263896</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hirabayashi</surname><given-names>J.</given-names></name><name><surname>Hashidate</surname><given-names>T.</given-names></name><name><surname>Arata</surname><given-names>Y.</given-names></name><name><surname>Nishi</surname><given-names>N.</given-names></name><name><surname>Nakamura</surname><given-names>T.</given-names></name><name><surname>Hirashima</surname><given-names>M.</given-names></name><name><surname>Urashima</surname><given-names>T.</given-names></name><name><surname>Oka</surname><given-names>T.</given-names></name><name><surname>Futai</surname><given-names>M.</given-names></name><name><surname>Muller</surname><given-names>W. E.</given-names></name><name><surname>Yagi</surname><given-names>F.</given-names></name><name><surname>Kasai</surname><given-names>K.</given-names></name></person-group> (<year>2002</year>) <source>Biochim. Biophys. Acta</source> <volume>1572</volume>, <fpage>232</fpage>&#8211;<lpage>254</lpage><pub-id pub-id-type="pmid">12223272</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lepp&#228;nen</surname><given-names>A.</given-names></name><name><surname>Stowell</surname><given-names>S.</given-names></name><name><surname>Blixt</surname><given-names>O.</given-names></name><name><surname>Cummings</surname><given-names>R. D.</given-names></name></person-group> (<year>2005</year>) <source>J. Biol. Chem.</source> <volume>280</volume>, <fpage>5549</fpage>&#8211;<lpage>5562</lpage><pub-id pub-id-type="pmid">15556936</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brewer</surname><given-names>C. F.</given-names></name><name><surname>Miceli</surname><given-names>M. C.</given-names></name><name><surname>Baum</surname><given-names>L. G.</given-names></name></person-group> (<year>2002</year>) <source>Curr. Opin. Struct. Biol.</source> <volume>12</volume>, <fpage>616</fpage>&#8211;<lpage>623</lpage><pub-id pub-id-type="pmid">12464313</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garner</surname><given-names>O. B.</given-names></name><name><surname>Baum</surname><given-names>L. G.</given-names></name></person-group> (<year>2008</year>) <source>Biochem. Soc. Trans.</source> <volume>36</volume>, <fpage>1472</fpage>&#8211;<lpage>1477</lpage><pub-id pub-id-type="pmid">19021578</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Blois</surname><given-names>S. M.</given-names></name><name><surname>Ilarregui</surname><given-names>J. M.</given-names></name><name><surname>Tometten</surname><given-names>M.</given-names></name><name><surname>Garcia</surname><given-names>M.</given-names></name><name><surname>Orsal</surname><given-names>A. S.</given-names></name><name><surname>Cordo-Russo</surname><given-names>R.</given-names></name><name><surname>Toscano</surname><given-names>M. A.</given-names></name><name><surname>Bianco</surname><given-names>G. A.</given-names></name><name><surname>Kobelt</surname><given-names>P.</given-names></name><name><surname>Handjiski</surname><given-names>B.</given-names></name><name><surname>Tirado</surname><given-names>I.</given-names></name><name><surname>Markert</surname><given-names>U. R.</given-names></name><name><surname>Klapp</surname><given-names>B. F.</given-names></name><name><surname>Poirier</surname><given-names>F.</given-names></name><name><surname>Szekeres-Bartho</surname><given-names>J.</given-names></name><name><surname>Rabinovich</surname><given-names>G. A.</given-names></name><name><surname>Arck</surname><given-names>P. C.</given-names></name></person-group> (<year>2007</year>) <source>Nat. Med.</source> <volume>13</volume>, <fpage>1450</fpage>&#8211;<lpage>1457</lpage><pub-id pub-id-type="pmid">18026113</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oberg</surname><given-names>C. T.</given-names></name><name><surname>Carlsson</surname><given-names>S.</given-names></name><name><surname>Fillion</surname><given-names>E.</given-names></name><name><surname>Leffler</surname><given-names>H.</given-names></name><name><surname>Nilsson</surname><given-names>U. J.</given-names></name></person-group> (<year>2003</year>) <source>Bioconjug. Chem.</source> <volume>14</volume>, <fpage>1289</fpage>&#8211;<lpage>1297</lpage><pub-id pub-id-type="pmid">14624646</pub-id></mixed-citation></ref></ref-list></back></article>